Login to Your Account

FDA OK of Pain Med Exalgo Brings Relief to CombinatoRx

By Donna Young

Wednesday, March 3, 2010
CombinatoRx Inc.'s shares jumped 33.3 percent Tuesday after the company and its U.S. commercialization partner Covidien plc said the FDA had approved Exalgo, a once-daily, extended-release formulation of hydromorphone, for moderate to severe pain in opioid-tolerant patients requiring continuous, around-the-clock opioid analgesia for an extended period of time. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription